Do-Youn Oh

27PUBLICATIONS
256CO-AUTHORS
Molecular targetsPredictive and prognostic markersChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|May 07, 2026
Promising New Platforms and Targets in the Management of Gastroesophageal Cancers.

|Apr 09, 2026
Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.

Vicky Makker, Jung-Yun Lee, Do-Youn Oh

|Mar 23, 2026
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.

Keun-Wook Lee, Elena Elimova, Do-Youn Oh

|Dec 29, 2025
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.

Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis

|Dec 01, 2025
Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.

Keun-Wook Lee, Li-Yuan Bai, Minkyu Jung

|Nov 18, 2025
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.

Marcia Cruz-Correa, Do-Youn Oh, Ken Kato

Pageof 5

Frequent Collaborators

6 joint publications

Funda Meric-Bernstam

6 joint publications

Keun-Wook Lee

5 joint publications

Josep Tabernero

4 joint publications

Teresa Macarulla Mercade